<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-608
Date of Submission: 2025-06-01

This report was submitted by a Patient from Mueller, Becker and Ryan Medical Center concerning patient ANON-PX-3978. The subject is a 66-year-old other with a significant medical history including osteoarthritis, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Intravenous route at a dosage of 232mg, initiated on 2025-05-02 for Pain and inflammation and discontinued on 2025-05-09.

On approximately 2025-05-08, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Dizziness, Anaphylaxis. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Dizziness was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-608
report_date: '2025-06-01'
patient_details:
  patient_id: ANON-PX-3978
  gender: Other
  relevant_history:
  - osteoarthritis
  - chronic kidney disease
  age_at_reaction: 66
suspected_drugs:
- drug_name: Ibuprofen
  dosage: 232mg
  route_of_administration: Intravenous
  start_date: '2025-05-02'
  indication_for_use: Pain and inflammation
  drug_class: NSAID
  end_date: '2025-05-09'
adverse_reactions:
- symptom_name: Headache
  onset_date: '2025-05-08'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: false
- symptom_name: Dizziness
  onset_date: '2025-05-08'
  severity: Moderate
  outcome: Recovering
  intervention_required: false
- symptom_name: Anaphylaxis
  onset_date: '2025-05-08'
  severity: Mild
  outcome: Not Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive rechallenge
reporting_facility: Mueller, Becker and Ryan Medical Center
reporter_type: Patient
